These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 20840390)
21. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152 [TBL] [Abstract][Full Text] [Related]
23. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Vaughan D; Speed J; Medve R; Andrews JS Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420 [TBL] [Abstract][Full Text] [Related]
24. PHARMACOKINETICS OF ORAL MAVACOXIB IN CARIBBEAN FLAMINGOS ( Huckins GL; Carpenter JW; Dias S; KuKanich B J Zoo Wildl Med; 2020 Mar; 51(1):53-58. PubMed ID: 32212546 [TBL] [Abstract][Full Text] [Related]
26. Bioavailability and pharmacokinetics of S-propargyl-L-cysteine, a novel cardioprotective agent, after single and multiple doses in Beagle dogs. Zheng Y; Xu J; Ma G; Zhang J; Zhu Q; Liu H; Zhang P; Zhu Y; Cai W Xenobiotica; 2012 Mar; 42(3):304-9. PubMed ID: 21961645 [TBL] [Abstract][Full Text] [Related]
27. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics. Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512 [TBL] [Abstract][Full Text] [Related]
29. Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. Nagilla R; Deshmukh DD; Copedge KJ; Miller S; Martin B; Bell EC; Duran SH; Ravis WR J Vet Pharmacol Ther; 2009 Feb; 32(1):49-55. PubMed ID: 19161455 [TBL] [Abstract][Full Text] [Related]
30. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics. Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of cimetidine in dogs after oral administration of cimetidine tablets. Le Traon G; Burgaud S; Horspool LJ J Vet Pharmacol Ther; 2009 Jun; 32(3):213-8. PubMed ID: 19646084 [TBL] [Abstract][Full Text] [Related]
33. Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). Dhondt L; Devreese M; Croubels S; De Baere S; Haesendonck R; Goessens T; Gehring R; De Backer P; Antonissen G Sci Rep; 2017 Sep; 7(1):12043. PubMed ID: 28947805 [TBL] [Abstract][Full Text] [Related]
34. The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. Collard WT; Hummel BD; Fielder AF; King VL; Boucher JF; Mullins MA; Malpas PB; Stegemann MR J Vet Pharmacol Ther; 2014 Jun; 37(3):279-85. PubMed ID: 24330031 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. Kim TW; Lebkowska-Wieruszewska B; Owen H; Yun HI; Kowalski CJ; Giorgi M Vet J; 2014 Apr; 200(1):77-81. PubMed ID: 24461644 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and bioavailability of topiramate in the beagle dog. Streeter AJ; Stahle PL; Holland ML; Pritchard JF; Takacs AR Drug Metab Dispos; 1995 Jan; 23(1):90-3. PubMed ID: 7720530 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration. Homedes J; Salichs M; Solà J; Menargues A; Cendrós JM; Encina G J Vet Pharmacol Ther; 2021 Nov; 44(6):888-901. PubMed ID: 34160092 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Reinoso RF; Farrán R; Moragón T; García-Soret A; Martínez L Biopharm Drug Dispos; 2001 Sep; 22(6):231-42. PubMed ID: 11754039 [TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Payne-Johnson M; Becskei C; Chaudhry Y; Stegemann MR Vet Rec; 2015 Mar; 176(11):284. PubMed ID: 25433056 [TBL] [Abstract][Full Text] [Related]
40. Dose-dependent emetic effects of the Amaryllidaceous alkaloid lycorine in beagle dogs. Kretzing S; Abraham G; Seiwert B; Ungemach FR; Krügel U; Regenthal R Toxicon; 2011 Jan; 57(1):117-24. PubMed ID: 21055413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]